Defunct Company
Total Trials
227
As Lead Sponsor
165
As Collaborator
62
Total Enrollment
35,624
NCT02610361
Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Nov 20, 2013
Completion: Oct 31, 2017
NCT02361723
Phase 1a/1b BGB-290 for Advanced Solid Tumors.
Start: Jul 3, 2014
Completion: Sep 3, 2019
NCT02343120
Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
Phase: Phase 1/2
Start: Sep 4, 2014
Completion: Mar 31, 2021
NCT02407990
Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors
Start: Jun 2, 2015
Completion: Aug 12, 2020
NCT03641586
The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor
Start: Oct 12, 2015
Completion: Mar 7, 2019
NCT02569476
BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
Start: Jan 13, 2016
Completion: Sep 2, 2020
NCT02660034
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
Start: Feb 2, 2016
Completion: Sep 9, 2020
NCT04163523
Study to Evaluate the Effect of Food on the Pharmacokinetics of a BGB-3111 in Healthy Subjects
Start: May 25, 2016
Completion: Jul 21, 2016
NCT02795182
Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies
Start: Jun 29, 2016
Completion: Dec 18, 2020
NCT03189524
A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma
Start: Jul 5, 2016
Completion: Aug 26, 2020
NCT03333915
Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors
Start: Dec 21, 2016
Completion: Aug 11, 2021
NCT04068519
Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody
Start: Dec 28, 2016
Completion: May 31, 2020
NCT03053440
A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)
Phase: Phase 3
Start: Jan 25, 2017
Completion: Jun 21, 2022
NCT03206970
Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Phase: Phase 2
Start: Mar 2, 2017
Completion: Sep 8, 2020
NCT03206918
Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Start: Mar 9, 2017
Completion: Sep 10, 2020
NCT04163783
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males
Start: Mar 29, 2017
Completion: Apr 18, 2017
NCT03209973
A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma
Start: Apr 21, 2017
Completion: Nov 2, 2020
NCT04004221
Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer
Start: Jun 16, 2017
Completion: Mar 11, 2021
NCT03150810
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
Start: Jun 28, 2017
Completion: May 4, 2023
NCT03145064
Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
Start: Jun 30, 2017
Completion: Sep 3, 2020
NCT03469557
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
Start: Jul 18, 2017
Completion: Aug 19, 2020
NCT03432598
Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer
Start: Aug 24, 2017
Completion: Dec 21, 2020
NCT03332173
Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)
Start: Aug 31, 2017
Completion: Jan 11, 2021
NCT03301181
Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects
Start: Sep 18, 2017
Completion: Nov 13, 2017
NCT03336333
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
Start: Oct 31, 2017
Completion: Sep 30, 2026
NCT03332017
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
Start: Nov 14, 2017
Completion: Dec 27, 2024
NCT03379259
Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors
Start: Nov 27, 2017
NCT03358875
Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)
Start: Nov 30, 2017
Completion: Jan 18, 2024
NCT03412773
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
Start: Dec 18, 2017
Completion: Dec 14, 2023
NCT03520920
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
Start: Jan 4, 2018
Completion: Aug 28, 2020
NCT03432884
A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects
Start: Jan 25, 2018
Completion: Apr 16, 2018
NCT03430843
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Start: Jan 26, 2018
Completion: Dec 28, 2022
NCT03419897
Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
Start: Apr 9, 2018
Completion: Jul 6, 2022
NCT03493451
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Start: Apr 13, 2018
Completion: Apr 21, 2021
NCT03519230
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
Start: May 14, 2018
Completion: Jun 30, 2027
NCT03465059
Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function
Start: May 30, 2018
Completion: Oct 19, 2018
NCT03561298
A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects
Start: Jun 7, 2018
Completion: Jul 2, 2018
NCT03575065
Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
Start: Jun 22, 2018
Completion: Apr 14, 2021
NCT03427814
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
Start: Jul 3, 2018
Completion: Jan 3, 2023
NCT03663205
A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
Start: Jul 23, 2018
Completion: Apr 26, 2023
NCT03594747
A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer
Start: Jul 30, 2018
Completion: Apr 28, 2023
NCT03736889
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Start: Sep 19, 2018
Completion: Sep 30, 2027
NCT03666143
A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Start: Nov 1, 2018
Completion: Jan 5, 2023
NCT03734016
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
Completion: Feb 28, 2024
NCT03744468
Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors
Start: Nov 13, 2018
Completion: Feb 6, 2025
NCT03783442
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Start: Dec 11, 2018
Completion: Aug 22, 2024
NCT03777657
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
Start: Dec 13, 2018
Completion: Aug 27, 2024
NCT03712930
Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency
Start: Feb 5, 2019
NCT03846427
Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma
Start: Feb 19, 2019
Completion: May 4, 2022
NCT03941873
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
Start: Feb 28, 2019
Completion: Mar 31, 2023
NCT03924986
Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
Start: Mar 27, 2019
Completion: Dec 8, 2023
NCT03905148
Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
Start: May 1, 2019
Completion: Feb 28, 2026
NCT03745222
A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer
Role: Collaborator
Start: May 22, 2019
Completion: Jun 26, 2019
NCT03967977
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
Start: May 29, 2019
Completion: Oct 21, 2027
NCT03991494
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer
Completion: Aug 5, 2020
NCT03994211
Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer
Completion: Aug 6, 2021
NCT03957590
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
Start: Jun 12, 2019
Completion: Mar 31, 2025
NCT04005716
Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
Start: Jul 22, 2019
Completion: Dec 29, 2023
NCT03933761
Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy
Start: Jul 29, 2019
Completion: Aug 2, 2021
NCT04047862
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
Start: Aug 15, 2019
Completion: Aug 7, 2024
NCT04002297
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
Start: Aug 20, 2019
Completion: Dec 31, 2027
NCT04116437
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
Start: Oct 15, 2019
Completion: Oct 31, 2025
NCT04164199
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Start: Dec 19, 2019
Completion: Dec 31, 2026
NCT04170283
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
Start: Jan 16, 2020
Completion: Dec 31, 2028
NCT04172246
Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
Start: Jan 29, 2020
Completion: Jun 30, 2025
NCT04215978
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Start: Jan 30, 2020
Completion: Jan 24, 2025
NCT03914742
BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
Start: Feb 16, 2020
Completion: Oct 31, 2023
NCT04221542
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Start: Mar 4, 2020
Completion: Mar 4, 2032
NCT04277637
Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
Start: Mar 24, 2020
Completion: Aug 30, 2027
NCT04276493
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
Start: Mar 26, 2020
Completion: Oct 31, 2024
NCT04282018
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
Start: May 25, 2020
Completion: Aug 28, 2024
NCT04379635
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
Start: May 29, 2020
NCT04382586
Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
Start: Jul 6, 2020
Completion: Feb 1, 2021
NCT04472650
Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults
Start: Jul 23, 2020
Completion: Nov 9, 2020
NCT04470908
The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males
Start: Jul 29, 2020
Completion: Nov 10, 2020
NCT04363801
A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
NCT04318080
Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
Start: Aug 20, 2020
Completion: Aug 29, 2024
NCT04486391
Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
Start: Sep 1, 2020
NCT04401800
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
Start: Sep 4, 2020
Completion: Feb 18, 2024
NCT04532294
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
Start: Sep 8, 2020
Completion: Feb 13, 2021
NCT04436107
Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Start: Sep 11, 2020
Completion: Mar 28, 2024
NCT04466891
A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers
Start: Oct 1, 2020
Completion: Jul 11, 2024
NCT04727996
Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer
Start: Nov 1, 2020
Completion: Dec 31, 2024
NCT04551963
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
Start: Nov 15, 2020
Completion: Feb 21, 2022
NCT04551898
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
Start: Dec 2, 2020
Completion: May 25, 2021
NCT04669262
BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants
Start: Dec 9, 2020
Completion: May 21, 2021
NCT04643470
Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
Start: Dec 22, 2020
Completion: Aug 26, 2024
NCT04521231
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Start: Jan 4, 2021
Completion: May 25, 2029
NCT04614909
Study of Pamiparib in Newly Diagnosed and rGBM
Phase: Early Phase 1
Start: Jan 11, 2021
Completion: Jul 31, 2026
NCT04776590
Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal Cancer
Start: Jan 28, 2021
Completion: Dec 15, 2024
NCT04693234
AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer
Start: Feb 15, 2021
Completion: Aug 31, 2023
NCT04649385
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
Start: Mar 4, 2021
Completion: Oct 31, 2026
NCT04579757
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Start: Mar 5, 2021
NCT04732494
Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Start: Mar 31, 2021
Completion: Dec 26, 2023
NCT04716634
Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
Start: Apr 19, 2021
Completion: Feb 22, 2024
NCT04771130
A Study of BGB-11417 in Participants With Myeloid Malignancies
Start: May 24, 2021
Completion: Feb 8, 2028
NCT04746924
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
Start: Jun 8, 2021
Completion: Mar 31, 2026
NCT04866017
A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer
Start: Jun 17, 2021
Completion: Oct 17, 2023
NCT04922047
Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)
Start: Jun 30, 2021
NCT04883957
Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies
Start: Jul 5, 2021
Completion: Apr 30, 2026
NCT04952597
Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer
Start: Jul 15, 2021
Completion: Jul 26, 2023
NCT04921358
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Start: Jul 27, 2021
Completion: Dec 20, 2023
NCT04577963
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
Start: Aug 9, 2021
Completion: Jun 18, 2024
NCT05068440
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
Start: Aug 11, 2021
NCT04974047
Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
Start: Aug 17, 2021
Completion: Oct 25, 2024
NCT04948697
A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC
Start: Aug 20, 2021
Completion: Feb 1, 2024
NCT05006716
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Start: Sep 13, 2021
Completion: Nov 30, 2029
NCT04973605
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Start: Sep 16, 2021
Completion: Nov 30, 2026
NCT05014828
To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors
Start: Sep 18, 2021
Completion: Jul 10, 2024
NCT04603365
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
Start: Oct 18, 2021
Completion: May 7, 2023
NCT05093270
First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study of BGB-23339 in Healthy Participants
Start: Nov 15, 2021
Completion: Dec 26, 2022
NCT05014815
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
Start: Nov 16, 2021
Completion: Sep 4, 2024
NCT05189457
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
Start: Jan 25, 2022
Completion: Jul 31, 2028
NCT05116085
Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer
Start: Jan 26, 2022
Completion: Jan 3, 2025
NCT05387668
Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects
Start: Feb 17, 2022
Completion: Oct 17, 2022
NCT05168930
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
Start: Feb 18, 2022
Completion: Oct 28, 2028
NCT05185531
A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma
Start: Mar 1, 2022
NCT05100862
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Start: Mar 10, 2022
Completion: Jun 30, 2030
NCT05245474
Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer
Start: Apr 1, 2022
Completion: Sep 1, 2029
NCT05267054
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
Start: Apr 25, 2022
Completion: Aug 30, 2024
NCT05245760
ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer
Start: Apr 30, 2022
Completion: Dec 31, 2033
NCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Start: May 6, 2022
NCT05316246
Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma
Start: Jun 1, 2022
NCT05373901
Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma
Start: Jun 7, 2022
Completion: Jun 29, 2023
NCT05547399
Relative Bioavailability of Zanubrutinib Tablets Compared to Capsules and Effects of Food on the Pharmacokinetics of the Tablet in Healthy Adults
Completion: Dec 7, 2022
NCT05286957
MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC
Start: Jun 20, 2022
Completion: Jun 1, 2027
NCT05350917
Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy
Completion: Jun 20, 2026
NCT05381909
A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
Start: Jul 6, 2022
NCT05431270
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Start: Aug 11, 2022
Completion: Aug 31, 2028
NCT05494762
Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors
Start: Aug 25, 2022
Completion: Feb 24, 2025
NCT05533892
Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC
Start: Sep 1, 2022
Completion: Feb 28, 2025
NCT05471843
Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Start: Sep 5, 2022
Completion: Jan 31, 2027
NCT05542342
Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
Start: Sep 23, 2022
Completion: May 6, 2025
NCT06239532
HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma
Start: Sep 27, 2022
Completion: Dec 31, 2025
NCT05461794
Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
Start: Oct 3, 2022
Completion: Feb 26, 2024
NCT05479994
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Start: Oct 24, 2022
Completion: Aug 25, 2027
NCT05590702
French Observational Study of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in Real-World Settings
Phase: N/A
Start: Nov 11, 2022
Completion: Dec 1, 2032
NCT05547828
Efficacy and Safety of Tislelizumab and Nab-paclitaxel Combined With Low-dose Radiotherapy in Patients With Stage IVb Esophageal Squamous Cell Carcinoma
Start: Dec 20, 2022
Completion: Dec 20, 2024
NCT05661955
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
Start: Jan 19, 2023
NCT05609370
A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
Start: Jan 29, 2023
NCT05840835
Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Start: Feb 3, 2023
Completion: Jan 24, 2024
NCT05445648
Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer
Start: Feb 28, 2023
NCT05640102
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
Start: Mar 3, 2023
NCT05635708
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
Start: Mar 7, 2023
NCT05767398
Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants
NCT05577702
Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
Start: Mar 15, 2023
Completion: Jan 23, 2025
NCT05707377
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
Phase: Phase 2/3
Start: Apr 17, 2023
Completion: Apr 30, 2028
NCT05650723
Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab
Start: May 8, 2023
NCT05844111
A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417
Start: May 22, 2023
Completion: Jun 18, 2023
NCT05828589
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
Start: Jun 20, 2023
Completion: Apr 30, 2027
NCT05564338
Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
Start: Jun 30, 2023
NCT05614453
Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy
Completion: Jun 28, 2023
NCT05904496
A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
Start: Jul 19, 2023
Completion: Aug 20, 2025
NCT05909904
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
Start: Jul 21, 2023
Completion: May 28, 2026
NCT05957757
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
Start: Aug 5, 2023
Completion: Jun 8, 2026
NCT05935098
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
Start: Aug 21, 2023
Completion: Mar 31, 2027
NCT05665530
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Start: Sep 12, 2023
NCT05981703
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Start: Sep 21, 2023
NCT05890352
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Start: Sep 26, 2023
Completion: Jan 31, 2029
NCT05952037
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
Start: Sep 28, 2023
NCT06029127
A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer
Start: Oct 23, 2023
NCT06010303
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Start: Nov 8, 2023
Completion: May 23, 2026
NCT05604560
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
NCT06073821
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
Start: Nov 11, 2023
Completion: Dec 31, 2032
NCT06091943
Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer
Start: Nov 16, 2023
NCT06120283
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Start: Dec 1, 2023
Completion: Jun 30, 2028
NCT05627115
Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma
Start: Mar 1, 2024
Completion: Oct 1, 2028
NCT05939037
Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related Polyneuropathy
Completion: Oct 1, 2027
NCT06257264
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Start: Mar 11, 2024
Completion: Feb 28, 2028
NCT05644626
Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants
Start: Mar 31, 2024
Completion: Aug 31, 2025
NCT06253195
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Start: Apr 1, 2024
Completion: Oct 26, 2026
NCT06233942
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Start: Apr 12, 2024
Completion: May 15, 2028
NCT06350318
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
Start: Apr 19, 2024
Completion: Mar 31, 2029
NCT05681195
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Start: Apr 25, 2024
Completion: Feb 28, 2031
NCT06029309
Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
Start: May 3, 2024
Completion: May 1, 2032
NCT05635162
Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma
Start: May 17, 2024
Completion: Oct 31, 2028
NCT06342713
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases
Start: Jun 3, 2024
NCT06456138
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
Start: Jul 1, 2024
NCT06093061
Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
Start: Jul 3, 2024
Completion: Oct 31, 2029
NCT06422520
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Start: Jul 8, 2024
NCT06487858
A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors
Start: Jul 16, 2024
NCT06427941
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Advanced or Metastatic Solid Tumors
Start: Jul 23, 2024
Completion: Oct 30, 2026
NCT06543043
A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers
Start: Aug 19, 2024
Completion: Nov 7, 2024
NCT06540066
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
Start: Aug 30, 2024
NCT06497062
Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Start: Sep 4, 2024
NCT06596473
A Study of BG-C477 in Participants With Advanced Solid Tumors
Start: Oct 3, 2024
Completion: Oct 27, 2028
NCT06589596
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
Start: Oct 11, 2024
NCT06598800
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
Start: Oct 18, 2024
Completion: Jan 31, 2028
NCT06630871
A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.
Start: Oct 31, 2024
NCT06520683
Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer
Start: Nov 1, 2024
Completion: Nov 1, 2030
NCT06585488
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Start: Nov 26, 2024
NCT06685718
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
NCT06634589
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Start: Nov 27, 2024
Completion: Dec 2, 2029
NCT06625593
A First-in-Human Study of BG-C137, an Anti-FGFR2b Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
Start: Dec 9, 2024
NCT06561347
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
Start: Dec 20, 2024
Completion: Dec 1, 2027
NCT06761898
A Study of Different Forms of BGB-43395 and Food Effect in Healthy Participants
Start: Jan 14, 2025
Completion: May 20, 2025
NCT06563596
Epco, Zanu, Ritux for R/R FL or MZL
Start: Jan 21, 2025
Completion: Mar 1, 2030
NCT06697184
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Start: Jan 23, 2025
NCT06776679
A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants
Start: Jan 24, 2025
Completion: Mar 27, 2025
NCT06764355
Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma
Start: Jan 31, 2025
NCT06756932
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
Start: Feb 4, 2025
Completion: Jul 30, 2027
NCT06685887
A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis
Start: Feb 15, 2025
NCT06558604
A Phase II Study Evaluating Glofitamab in Combination With Venetoclax Plus Zanubrutinib or Venetoclax Alone in Subjects With Untreated or Relapsed/Refractory High-risk Mantle-cell Lymphoma
Start: Feb 28, 2025
Completion: Mar 31, 2032
NCT06742996
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma
Start: Mar 5, 2025
Completion: Oct 30, 2032
NCT06803680
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
Start: Mar 18, 2025
Completion: Oct 30, 2027
NCT06906809
Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants
Start: Apr 3, 2025
Completion: Oct 13, 2025
NCT06846671
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Start: Apr 10, 2025
Completion: Feb 14, 2030
NCT06332274
tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
Start: Apr 16, 2025
Completion: Apr 30, 2030
NCT06730542
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
Start: Apr 17, 2025
NCT06970743
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
Start: May 29, 2025
NCT06547866
Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia
Start: Jun 1, 2025
Completion: Dec 31, 2031
NCT07012980
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
NCT06839053
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Start: Jun 2, 2025
Completion: Jul 1, 2032
NCT06943872
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Start: Jun 11, 2025
NCT07039162
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
Start: Jul 1, 2025
NCT07005713
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria
Start: Jul 19, 2025
Completion: Sep 22, 2026
NCT05690035
Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer
Start: Jul 31, 2025
Completion: Jul 31, 2025
NCT07100938
A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis
Start: Aug 21, 2025
Completion: Oct 18, 2026
NCT07043400
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Start: Aug 27, 2025
Completion: Apr 22, 2028
NCT06854003
BRAZAN Trial in Frontline MCL
Start: Aug 31, 2025
Completion: Nov 1, 2039
NCT07059299
A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
Completion: Aug 31, 2027
NCT06973187
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Start: Sep 4, 2025
Completion: Apr 17, 2028
NCT07136077
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
Start: Sep 18, 2025
Completion: Apr 1, 2028
NCT07141511
A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults
Start: Sep 30, 2025
Completion: Jan 3, 2026
NCT07169331
A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia
Phase: Phase 4
Start: Oct 15, 2025
NCT07181681
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
Start: Oct 22, 2025
Completion: Nov 1, 2027